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Supplemental Methods 
Details of excluded patients 
5 of 22 children from the UK and Ireland presenting with aHUS and anti-FH autoantibodies 
at a titre above the international consensus positive threshold of 100 RU were excluded from 
this study because: 1 child had Shiga toxin associated HUS and the low titre autoantibody 
was not felt to be significant; 1 individual presented aged 7 years with aHUS in 1992, but did 
not have serum tested for autoantibodies until 22 years later (the clinical course was of 
multiple relapses in childhood, treated with plasma exchange (PEX) and intravenous 
immunoglobulin (IVIG), and peritoneal dialysis for year before recovery of renal function – 
which has been stable since); 1 individual had serum tested for autoantibodies 10 years after 
presenting with aHUS; in 2 individuals the initial assay was positive but no samples were 
available to confirm positivity using the international consensus assay. 
eGFR calculation 
The estimated glomerular filtration rate (eGFR) was calculated: for children (<18 years), the 
Schwartz formula was used: eGFR (mL/min/1.73 m2) = [ 0.55 x height (centimetres) x K 
(constant) ] / serum creatinine (μmol/L) x 0.0113 (correction factor for mg/dL); in first year of 
life, for pre-term babies K=0.33 and for full-term infants K=0.45; for infants and children 
between ages of 1 and 12 years, K=0.55; adolescent boys, K=0.7. For adults the 
abbreviated MDRD equation was used: 186 x (Creat / 88.4)-1.154 x (Age)-0.203 x (0.742 if 
female) x (1.210 if black). 
Factor H autoantibody assay 
The consensus assay was performed as previously described1. A 96 well Maxisorbtm ELISA 
plate (Nunc) was coated with 50µl/well of purified factor H (CompTech, Tyler, Texas, USA) 
at 5µg/ml or molar equivalents of factor H fragments (short consensus repeats [SCRs] 1-7 
(generated in house) 8-15, 19-20)2, 3 or factor H–related protein 1 fragment (SCRs 4-5)4 in 
Dulbecco’s PBS (137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.4) 
and incubated overnight at 4°C. Alternatively, for detection of circulating immune complexes 
(CIC) plates were coated with OX24 (2µg/ml) in 0.1M carbonate buffer, pH 9.6. Plates were 
washed once with PBS, then blocked with 200µl PBS/0.1% Tween (PBS-T) per well for 1hr 
at room temperature (for CIC, plates were blocked with 1% BSA/PBS-T). A second (replicate) 
plate was incubated with block only. Plates were washed 3 times with PBS/0.1% Tween. 
Individual test samples were diluted then 1/50 in PBS-T and 50 µl applied in triplicate to 
each plate, including a positive, negative and ‘no serum’ control. A standard curve was 
established using positive sample applied in doubling dilution from 1/25 to 1/3200. Samples 
and controls were incubated for exactly 1hr at room temperature followed by 3 washes with 
PBS-T. A 1/20,000 dilution of HRP conjugated goat anti-human IgG (Stratech Scientific Ltd, 
UK) in PBS-T (50µl/well) was then applied for exactly 1 hour. Both test and control plates 
were washed 3 times with PBS-T, 50µl/well of TMB substrate was applied (readymade, 
Leico Technologies) and plates developed for 5-10min. The reaction was stopped using 
50µl/well 10% H2SO4 and OD450nm measurements taken using an EL-800 plate reader 
(Biotek, UK). The readings from the ‘block only’ plate were then subtracted from the factor H 
coated plate. An ELISA was considered valid when the range between positive and negative 
control was greater than 1.0 (OD450). Readings from the background subtracted positive 
control standard curve were assigned 4000 relative units (RU) for a 1/25 dilution of 
Newcastle positive serum. These were plotted using PrismGraph 3 software, which allowed 
automatic interpolation of sample RU from a curve fit based on four-parameter logistic non-
linear regression. Samples were analysed on three individual experiments and the mean of 
these used in the figures herein. 
Western blotting confirmation of factor H autoantibody.  
Purified complement factor H (Comptech) was diluted in solubilizing buffer (non-reducing) 
and loaded onto a 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) preparative gel. After transfer to nitrocellulose and blocking as described previously, 
the nitrocellulose was cut into 0.5- to 1-cm wide strips. These strips were then incubated with 
individual sera samples (1/100 in 5% dried milk/PBS) for 1 to 2 hours at room temperature. 
After washing as described previously, bound autoantibody was detected by the use of goat 
anti-human IgG-HRP incubated for 1 to 2 hours at room temperature. Blots were then 
washed twice with PBS/0.01% Tween 20 and with PBS only. All blots were developed by the 
use of an enhanced chemiluminescence (ECL) substrate (Pierce) according to the 
manufacturer’s specifications. 
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Supplemental Figure 1: Serum creatinine and platelet values at presentation
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Supplemental Figure 2: Initial complement antigenic levels. A. C3. Normal in 76% of patients. B. 
C4. Normal in 71% of patients. C. Factor I. Normal in all patients.
The dashed lines represent the lower limit of the normal ranges. 
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Supplemental Figure 3: C4 level and FH/autoantibody circulating immune complexes
Abbreviations: RU, relative units
Supplemental Table 1: Autoantibody reactivity with short factor H fragments.
CFHR1 copy number and autoantibody binding to factor H fragments (SCRs 1-7, 8-15, 16-18 and 19-20)
(positive threshold >100RU). 
Abbreviations: SCR = Short Consensus Repeat.
Patient CFHR1 copy number SCRs 1-7 SCRs 8-15 SCRs 16-18 SCRs 19-20
2
4
5
6
10
12
14
15
16
17
18
19
20
21
22
23
24
0
0
0
2
0
0
0
0
0
0
0
2
0
0
2
0
0
130
7
235
3126
0
41
33
7
0
1
42
5
46
496
327
0
0
0
0
3
9
0
450
60
0
0
3
0
0
0
76
0
0
0
24
0
57
615
0
0
0
81
0
0
0
0
0
0
13
0
104
613
2171
144
0
1570
377
2365
2245
239
2370
981
410
219
2714
1
1050
3243
Supplemental Table 2: Initial titres of factor H autoantibody (aFH), circulating immune 
complexes (CiC), and autoantibody reactivity with factor H–related proteins 1-5 (positive 
threshold >100RU) 
Abbreviations: aFH, factor H autoantibody; CiC, circulating immune complexes; FHR, factor H related proteins; RU, relative units.
Patient aFH CiC FHR1 FHR2 FHR3 FHR4 FHR5
2 630 357 694 74 0 0 0
4 1249 0 792 0 0 0 21
5 573 812 0 352 147 169 43
6 2017 0 0 0 0 0 0
10 3432 840 612 0 0 0 0
12 812 350 0 0 0 0 0
14 722 0 132 0 0 29 3
15 4000 450 1380 65 39 0 0
16 4000 0 1350 0 0 0 45
17 2194 75 600 0 0 0 41
18 2130 490 900 22 0 0 0
19 2319 0 500 0 0 0 0
20 1594 106 0 0 0 0 0
21 971 0 700 0 0 0 0
22 277 0 0 0 37 30 21
23 1350 474 279 0 359 468 341
24 3396 1307 2645 0 0 20 0
Supplemental Figure 4: Outcome according to dialysis requirement at presentation.
75% of patients who required dialysis within one week of presentation fully recovered renal function.
*Defined as dialysis within the first week of presentation
**Defined as recurrence >1 month after presentation and >15 days after disease remission
† Management: supportive:1, PEX:1
‡ Management: PEX:4, eculizumab: 2
Abbreviations: ERF, established renal failure; PEX, plasma exchange.
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Supplemental Table 3: Treatment modality and resultant renal function 
eGFR: by Schwartz formula for patients <18 years at last follow up (*) and by abbreviated MDRD equation for patients >18 at last follow up (†) 
Abbreviations: AMR, antibody mediated rejection; CS, corticosteroids; ECU, eculizumab; eGFR: estimated glomerular filtration rate; ERF, 
established renal failure; FFP, fresh frozen plasm; IVIG, intravenous immunoglobulin; MMF, mycophenolate mofetil; n/a, not applicable; PEX, 
plasma exchange; RTX, rituximab; SUP, supportive management. 
Patient Treatment at 
first 
presentation 
Dialysis 
(duration if 
recovery) 
ERF Relapse Renal 
Transplant 
Subsequent 
treatment 
Duration of 
follow up 
(months) 
eGFR 
(mL/min/1.73m2) 
at most recent follow up 
2 FFP, PEX Yes (5 weeks) No Yes n/a PEX at relapse 163 >60† 
4 FFP, PEX, IVIG Yes Yes No Yes 
aHUS recurrence 
ECU post-transplant 75 47.6* 
5 PEX Yes Yes No Yes 
Graft failure (AMR) 
 151 ERF 
6 PEX Yes Yes No No. Ineligible  130 ERF 
10 PEX, CS No No Multiple n/a Regular PEX, 
withdrawn 2012 
117 >60* 
12 FFP, PEX, IVIG Yes Yes No Yes  98 >60* 
14 FFP, ECU No No No n/a  7 >60* 
15 ECU Yes (5 days) No No n/a  11 >60* 
16 PEX Yes (3 days) No Yes n/a ECU at relapse 81 >53* 
17 PEX No No No n/a  108 >60* 
18 FFP, PEX No No Yes n/a PEX at relapse 123 >60* 
19 SUP Yes Yes No Yes  64 48.4* 
20 ECU No No No n/a  62 >60* 
21 FFP, PEX Yes (6 days) No Yes n/a PEX, RTX at relapse 9 >60† 
22 SUP Yes Yes No Yes  84 >60* 
23 PEX Yes (5 days) No No n/a  12 >60* 
24 ECU Yes (5 weeks) No No n/a  22 52.3* 
0 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
17 11 8 6 6 6 6 5 5 4 4 4 4 4 3 3 3 3 3 3 2 1
Supplemental Figure 5: Kaplan Meier survival curve showing probability of renal survival
35% of patients developed ERF, and in all cases this occurred at the first presentation of aHUS. There were no deaths.
Supplemental Table 4: Comparison with other cohorts 
 
Abbreviations: CKD, chronic kidney disease; ERF, established renal failure; FH, factor H; IS, immunosuppression; IVIG, intravenous immunoglobulin; N/A, not available; n/a, not applicable; PEX, plasma exchange; PI, plasma infusion; TR, treatment resistance. 
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al.15 
Moore et al.9 UK and Ireland 
# Patients 45 (38 children) 4 children 138 children 15 children 6 children 8 (6 children) 7 children 25 children 13 children 17 children 
Age (years) Median 8.5 (children only) Mean 6 Mean 8.4 Mean 8 1-7 years at 
onset in 83.3% 
N/A Mean 5.2 Mean 7.9 Median 8 Median 8 
% Male 66% (children only) N/A 72.5% 27% 50% 50% N/A N/A 46% 65% 
Gastrointestinal symptoms 84% (diarrhoea 53%) 25% Diarrhoea 9.4% Diarrhoea 13% 83% 14.3% N/A 87% N/A 75% (diarrhoea 50%) 
Extra-renal 
manifestations 
50% hepatitis 
23% pancreatitis 
23.5% seizures 
N/A 57.3% hepatic 
40.6% seizures 
7% hepatitis 
7% pancreatitis 
7% CNS 
N/A 14.3% CNS N/A 11% CNS 
58% other 
N/A 19% seizures 
13% hepatitis 
6% pancreatitis 
Concomitant rare genetic 
variants 
0/26 0 N/A 0/15 2/6 (33%): CFI, 
C3
2/8 (25%): 
CFH x2 
0/7 1/8 (12.5%): 
CFI
5/13 (38%): CFH, 
CFI, CD46, C3 x2 
7/17 (41%): CFH, 
CFI x4, CD46, C3 
 Complement 
analysis 
Low C3 58% 50% 62% 67% N/A 43% 57% 41% 27% 24% 
Low C4 0 N/A N/A N/A N/A 14% 14% 15% 27% 29% 
Low FH 22% N/A N/A N/A N/A 29% 0 N/A 9% 12% 
Treatment and evolution of first episode 
Supportive 6 (13% of total): ERF 1 (17%); 
relapses 2 (33%); TR 1 (17%); 
CKD 1 (17%) 
0 N/A N/A 2 (33%) N/A N/A N/A 10 (77%) 2 (12% of total): ERF 
2 (100%) 
PI 6 (13% of total): relapses 5 
(83%), TR 1 (17%) 
0 N/A 91% N/A N/A N/A N/A N/A n/a 
PEX 15 (33% of total): ERF 1 (7%); 
death 1 (7%); CKD 3 (20%); TR 
3 (20%); relapses 6 (40%) 
0 105 (76%) in total 69% N/A N/A N/A N/A 3 (23%) 11 (65% of total): 
ERF 4 (36%); 
relapses 5 (45%) 
PEX or PI N/A 0 N/A N/A 4/6 (67%) 
(chronic in 3) 
7/8 (87.5%) 
 
5/7 (71%) 18/19 (95%) N/A n/a 
PEX + Corticosteroids 0 0 N/A N/A N/A 3/8 (37.5%): 
remission in 
2/3 (67%) 
1 N/A N/A 1 
PEX + Immunosuppression 3 (6.7% of total) 4 (100%) 87 (63%) IS 7 (54%) 
steroids +/- IS 
0 3/8 (37.5%) 2 (29%) 
 
0 0 0 
 Azathioprine 0 0 N/A N/A n/a 0 1 n/a n/a n/a 
Steroids + 
cyclophosphamide 
2: no renal sequelae 4 (at relapse in 
patient treated with 
rituximab) 
49 N/A n/a 0 0 n/a n/a n/a 
Steroids + 
rituximab 
0 (rituximab initially 
in 1) 
18 N/A n/a 0 0 n/a n/a n/a 
Steroids + MMF 1: no renal sequelae 0 N/A N/A n/a 0 0 n/a n/a n/a 
Eculizumab 0 0 0 0 0 0 0 0 0 4 (24% of total): 
100% sustained 
remission 
Maintenance 
Immunosuppression 
N/A n/a 47 (34%): steroids alone 
21; plus azathioprine 8; 
plus MMF 18 
N/A n/a N/A N/A n/a n/a 0 
Long term outcomes 
Sustained remission N/A 
(25% no renal sequelae) 
100% after 
cyclophosphamide 
N/A 62% no 
sequelae 
0 12% complete 
remission 
N/A N/A N/A n/a 
Relapse 58% 25% (following 
rituximab in 1) 
14 (11.5%); 
(4 whilst on IS) 
31% 50% 37.5% N/A N/A 23% 29% overall 
ERF 27% 0 32.8% 0 0 63% 43% N/A 46% 35% overall 
CKD (not including ERF) 39% 0 N/A 15% N/A N/A N/A N/A N/A CKD stage 3: 1 (6%) 
Death 4 (8.9%) 0 20 (16.4%) 0 1 (16.7%) 0 1 (14.3%) N/A 0 0 
 Deaths: unknown; sudden death 
post dialysis; pulmonary 
hypertension; cardiac 
insufficiency 
n/a Deaths: complications of 
renal failure 16; sepsis 4 
n/a N/A n/a Death: 
myocarditis 
N/A n/a n/a 
Outcome of transplantation 
Recurrence 3 without specific management n/a 0 n/a 0 1 0 N/A 0 1 early recurrence 
(CFI mutation) 
treated with 
Eculizumab 
No recurrence 3 with specific management n/a 3 with specific 
management 
(PEX/IVIG/rituximab) 
n/a 0 0 2 N/A 3 4 without specific 
management (1 graft 
loss rejection) 
